PharmacoEconomics & Outcomes News 792, p31 - 2 Dec 2017 Benefits of proposed faster drug approval in the UK questionable The UK’s government proposed scheme of accelerated access to new drugs and technologies is unlikely to improve patient outcomes, say professors of health policy from the London School of Economics and Political Science in London, UK. In their comment published in the BMJ, the professors question the benefits of the proposed scheme, which aims to expedite development and approval of promising new technologies, and their adoption in the NHS. The professors caution that, according to research, most products with accelerated approval "do not offer a step change in patient outcomes". The proposal "says too little on expected benefits for patients and wider society," note the professors. They also suggest that another important issue is that the selection process of such promising technologies relies on early studies, which tend to exaggerate benefits. Furthermore, they caution that faster access to new drugs and technologies is more likely to escalate, rather than control healthcare spending. Innovations that save money are very rare, and it is doubtful that the extra costs can be offset by identifying and expediting other products that generate savings. The proposal of accelerated access is a "bold attempt to strike a balance between health and industrial policy," note the professors. They conclude "we should focus on better not faster approvals and send a clear message to industry about the needs and priorities of the NHS and all who use it." Naci H, et al. Accelerated access to new drugs and technologies BMJ : 22 Nov 2017. Available from: URL: https://doi.org/10.1136/bmj.j5387 803284964 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera